Freenome
Blood-based cancer screening built on multiomic, AI-driven detection.
$14.60
After-hours close−0.18 (−1.22%)
At close$14.78(+6.03%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders 58.06%
Shares outstanding 8.16M · Float 7.12M
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLC | 10 percent owner | 12.58M | 154.25% | Jul 22, 2026 |
| Riley Charles Ennis | officer: Chief Product Officer | 2.86M | 35.11% | Jul 27, 2026 |
| Perceptive Capital Solutions Holdings | other: Former 10% Owner | 2.35M | 28.84% | Jul 23, 2026 |
| Stone Adam Leo | other: Former Dir, Ofc, 10% Ownr | 2.35M | 28.84% | Jul 22, 2026 |
| Ra Capital Management, L.P. | director | 750.0K | 9.19% | Jul 22, 2026 |
| Aaron Matthew Elliott | director, officer: Chief Executive Officer | 417.9K | 5.12% | Jul 27, 2026 |
| Cheng-Ho Jimmy Lin | officer: Chief Scientific Officer | 410.2K | 5.03% | Jul 27, 2026 |
| Randal W. Scott | director | 104.2K | 1.28% | Jul 27, 2026 |
| H. le Linh | officer: Chief Financial Officer | 64.3K | 0.79% | Jul 27, 2026 |
| Harlan Waksal | other: Former Director | 30.0K | 0.37% | Jul 29, 2026 |
3 ten-percent owners hold 17.29M shares by Form 4, outside the officers-and-directors figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.